SCHEMBL5652732

SCHEMBL5652732

COc1ccc(N2C(=O)CCC2=O)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.54
LMNA P02545 1/20 0.47
CHRNB2 P17787 4/20 0.47
CHRNA4 P43681 4/20 0.47
NPC1 O15118 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GAA P10253 1/20 0.43
CHRNB4 P30926 2/20 0.43
CHRNA3 P32297 2/20 0.43
GLA P06280 1/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
HSD17B3 P37058 1/20 0.41
NNMT P40261 1/20 0.41
OPRM1 P35372 1/20 0.40
OPRL1 P41146 1/20 0.40
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5650408 0.92 L3MBTL1 (0.48) POLBL3MBTL1LMNACHRNB2CHRNA4
SCHEMBL5648177 0.84 POLB (0.48) POLBL3MBTL1CHRNB2CHRNA4CHRNB4
SCHEMBL28752511 0.81 MGLL (0.55) CHRNB2CHRNA4CHRNB4CHRNA3KMT2A
Hydrochloric Acid SCHEMBL4989305 0.79 SMN1; SMN2 (0.43) L3MBTL1LMNACHRNB2CHRNA4NPC1
SCHEMBL29741499 0.78 SMN1; SMN2 (0.65) CHRNB2CHRNA4NPC1HTTSMN1; SMN2
SCHEMBL31439068 0.77 NR1H3 (0.50) HTTGAAKMT2AMEN1CA9
SCHEMBL1359572 0.77 CHRNB2 (0.58) CHRNB2CHRNA4NPC1HTTSMN1; SMN2
SCHEMBL11619876 0.77 NR1H3 (0.50) HTTGAAKMT2AMEN1CA9
SCHEMBL1358649 0.76 NPC1 (0.60) CHRNB2CHRNA4NPC1HTTSMN1; SMN2
SCHEMBL25890537 0.75 POLB (0.49) POLBL3MBTL1CHRNB2CHRNA4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL POLB 3606/4885L3MBTL1 1427/4885LMNA 1410/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL POLB 2734/4885L3MBTL1 2654/4885LMNA 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.